fda bpc-157 warning 2025 news panel backs compounded BPC-157, KPV peptides in win for RFK Jr Advisers to the FDA back

Advisers to the FDA back broad access to unapproved peptides, despite agency concerns A step towards expanded patient access. This will allow patients to have conversations about these compounds in the clinical setting instead of resorting to a gray market without practitioner oversight or monitoring! FDA scientists flag concerns with peptides as RFK Jr. tries to ease access : NPR FDA panel narrowly backs unapproved peptide drugs favored by RFK Jr. and wellness influencers

SKU: 54442217482 · From iglepidom.org